VRDN — Viridian Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$22.66
-$0.37 (-1.58%)
Viridian Therapeutics Inc (VRDN) is a biotechnology company listed on NASDAQ. It is led by Stephen F. Mahoney J.D., MBA, based in 221 Crescent Street, Waltham, MA, United States, 02453, with about 143 employees. Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Net income was -$34.6M. VRDN currently screens at market cap $1.39B.
Use this VRDN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VRDN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VRDN SEC filings page. Lician reads the product cache first so this HTML stays unique to Viridian Therapeutics Inc even when a live quote feed is slow.
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
VRDN Key Statistics
Market Cap
$1.39B
Volume
901,227
Previous Close
$24.02
Day Range
$24.08 – $24.80
EPS
$0.00
Revenue
$0.00
Net Income
-$269.95M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
143
VRDN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$269.95M | -$237.73M | -$129.87M | -$79.41M |
| EPS (Diluted) | $0.00 | -$5.31 | -$4.05 | -$6.66 |
Total Assets
$742.40M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
-$232.32M
Free Cash Flow
$0.00
Viridian Therapeutics Inc Company Information
- CEO, President & Director
- Stephen F. Mahoney J.D., MBA
- Headquarters
- 221 Crescent Street, Waltham, MA, United States, 02453
- Website
- www.viridiantherapeutics.com
- Phone
- 617 272 4600
- IPO / Founded
- 2014-06-18
- Sector
- Healthcare
- Industry
- Biotechnology